Curated News
By: NewsRamp Editorial Staff
June 25, 2026

Helus Pharma Raises $50M in Public Offering to Advance Mental Health Pipeline

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Helus Pharma raised $50M to advance its clinical pipeline, potentially gaining a first-mover advantage in novel depression treatments.
  • Helus Pharma closed an underwritten public offering of 10.3M shares at $4.85, netting $50M for Phase 3 trials of HLP003 and other candidates.
  • Helus Pharma develops novel serotonergic agonists to treat depression and anxiety, aiming to improve mental health outcomes for millions.
  • Helus Pharma's NSA drugs target serotonin pathways to promote neuroplasticity, offering a new approach to mental health treatment.

Impact - Why it Matters

This news matters because Helus Pharma is developing innovative treatments for major depressive disorder and generalized anxiety disorder, conditions that affect millions worldwide. The $50 million funding will accelerate clinical trials for HLP003 and HLP004, potentially bringing new, more effective therapies to patients who have not responded to existing treatments. With Breakthrough Therapy Designation for HLP003, the company is positioned to address a significant unmet need in mental health, offering hope for durable improvements in neuroplasticity and symptom relief.

Summary

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has successfully closed its underwritten public offering of 10,309,280 common shares at US$4.85 per share, raising approximately US$50 million in gross proceeds. The offering was managed by joint bookrunning managers Cantor and Barclays, with Bloom Burton Securities and Lucid Capital Markets serving as lead managers. The company paid US$3 million in cash commissions to the underwriters and plans to use the net proceeds to advance its clinical pipeline, including HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder, and HLP005, while also supporting working capital and general corporate purposes. Phase 3 APPROACH data for HLP003 is expected in the fourth quarter of 2026.

Helus Pharma is a clinical stage pharmaceutical company founded in 2019, focused on developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways and promote neuroplasticity. Their lead candidate, HLP003, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of major depressive disorder and is currently in Phase 3 clinical development. HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more details, visit the full press release at https://ibn.fm/bSYLT.

This news was distributed by MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. MissionIR helps IR firms enhance visibility for private and public companies through syndicated content, press release enhancement, and social media distribution. The company’s newsroom for latest updates on HELP is available at https://ibn.fm/HELP.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Raises $50M in Public Offering to Advance Mental Health Pipeline

blockchain registration record for this content.